mankhwala atsopano osakhala ang'onoang'ono a khansa ya m'mapapo

Khansara ya m'mapapo yosakhala yaying'ono (NSCLC) ndiyomwe imayambitsa kufa kwa khansa padziko lonse lapansi. Mwamwayi, kupita patsogolo kwakukulu muzosankha zamankhwala kukubwera, kumapereka chiyembekezo chatsopano chazotsatira zabwino komanso moyo wabwino. Nkhaniyi ikufotokoza zaposachedwa mankhwala atsopano osakhala ang'onoang'ono a khansa ya m'mapapoKumvetsetsa Khansa Yam'mapapo Yopanda Yang'ono (NSCLC)Non-small cell lung cancer (NSCLC) ndi khansa ya m'mapapo yofala kwambiri, yomwe imatenga pafupifupi 80-85% ya matenda onse a khansa ya m'mapapo. Amaphatikiza mitundu ingapo, kuphatikiza adenocarcinoma, squamous cell carcinoma, ndi cell carcinoma yayikulu. Gawo la NSCLC pakuzindikira limakhudza kwambiri njira zamankhwala komanso momwe mungadziwire. NSCLC yoyambirira ikhoza kuchiritsidwa ndi opaleshoni, pamene magawo apamwamba nthawi zambiri amafunika kuphatikiza mankhwala ochiritsira. Njira zochiritsirazi nthawi zambiri zimakhala zogwira mtima komanso zimakhala ndi zotsatirapo zochepa poyerekeza ndi mankhwala achikhalidwe. Zolinga zodziwika bwino mu NSCLC zikuphatikizapo EGFR, ALK, ROS1, BRAF, ndi MET.EGFR InhibitorsEpidermal growth factor receptor (EGFR) ndi mapuloteni omwe amathandiza maselo kukula ndi kugawa. Zotupa zina za NSCLC zimakhala ndi masinthidwe amtundu wa EGFR, zomwe zimatsogolera kukula kosalamulirika kwa maselo. EGFR inhibitors, monga gefitinib, erlotinib, afatinib, ndi osimertinib, amalepheretsa ntchito ya EGFR, kuchepetsa kapena kuletsa kukula kwa chotupa.Ubwino: Nthawi zambiri zimakhala zogwira mtima kwa odwala omwe ali ndi kusintha kwa EGFR, zomwe zimapangitsa kuti akhale ndi moyo wabwino komanso moyo wabwino.Zotsatira zake: Kuthamanga pakhungu, kutsekula m'mimba, kutopa.Osimertinib nthawi zambiri ndiyo njira yoyamba yothandizira EGFR-mutated NSCLC, kusonyeza mphamvu yapamwamba poyerekeza ndi EGFR inhibitors oyambirira. Mukhoza kuphunzira zambiri za EGFR inhibitors kuchokera ku Webusaiti ya American Cancer Society.ALK InhibitorsAnaplastic lymphoma kinase (ALK) ndi mapuloteni ena omwe amatha kusinthidwa mu NSCLC. ALK inhibitors, monga crizotinib, ceritinib, alectinib, brigatinib, ndi lorlatinib, amayang'ana mapuloteni a ALK, kulepheretsa ntchito yake ndikuletsa kukula kwa chotupa.Ubwino: Kuchita bwino kwa odwala omwe ali ndi ALK rearrangements, zomwe zimapangitsa kuti moyo ukhale wabwino komanso kuchepetsa kukula kwa matenda.Zotsatira zake: Kusintha kwa masomphenya, nseru, kusanza, kutsekula m'mimba, kutopa.Alectinib ndi Lorlatinib nthawi zambiri amakonda mankhwala oyamba chifukwa cha kuwongolera kwawo komanso kuthekera kolowera chotchinga chamagazi-muubongo, zomwe ndizofunikira kwa odwala omwe ali ndi metastases muubongo. Kafukufuku wa Cancer UK imapereka zambiri zowonjezera.ROS1 InhibitorsROS1 ndi receptor tyrosine kinase yomwe, ikaphatikizidwa ndi jini ina, imatha kuyendetsa kukula kwa khansa. ROS1 inhibitors, monga crizotinib ndi entrectinib, amagwiritsidwa ntchito pochiza NSCLC ndi ROS1 fusions.Ubwino: Kuchepa kwa chotupa chachikulu komanso kukhala ndi moyo wautali kwa odwala omwe ali ndi ROS1-positive NSCLC.Zotsatira zake: Mofanana ndi ALK inhibitors.Entrectinib yasonyeza lonjezo chifukwa cha mphamvu yake yodutsa malire a ubongo wa magazi, kuti ikhale yothandiza pochiza metastases ya ubongo. Onani Webusaiti ya European Medicines Agency kuti mudziwe zambiri.Immunotherapy ya NSCLCImmunotherapy imagwiritsa ntchito mphamvu zachitetezo cha thupi kuti kulimbana ndi khansa. Immune checkpoint inhibitors ndi mtundu wa immunotherapy umene umatchinga mapuloteni omwe amalepheretsa chitetezo cha mthupi kumenyana ndi maselo a khansa.PD-1/PD-L1 InhibitorsProgrammed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) ndi mapuloteni omwe amathandiza maselo a khansa kuthawa chitetezo cha mthupi. PD-1/PD-L1 inhibitors, monga pembrolizumab, nivolumab, atezolizumab, ndi durvalumab, amaletsa mapuloteniwa, kulola kuti chitetezo cha mthupi chizindikire ndikuukira maselo a khansa.Ubwino: Mayankho okhazikika komanso kupulumuka bwino m'gulu la odwala omwe ali ndi NSCLC.Zotsatira zake: Zotsatira zokhudzana ndi chitetezo chamthupi, monga chibayo, colitis, ndi hepatitis.Pembrolizumab nthawi zambiri amagwiritsidwa ntchito ngati chithandizo choyamba kwa odwala a NSCLC omwe ali ndi mawu apamwamba a PD-L1. Zambiri zitha kupezeka pa Webusaiti ya FDA.CTLA-4 InhibitorsCytotoxic T-lymphocyte-associated protein 4 (CTLA-4) ndi mapuloteni ena omwe amatha kupondereza chitetezo cha mthupi. Ipilimumab ndi CTLA-4 inhibitor yomwe ingagwiritsidwe ntchito limodzi ndi PD-1 inhibitors kuti ipititse patsogolo chitetezo chamthupi ku maselo a khansa.Ubwino: Zitha kupititsa patsogolo kupulumuka zikaphatikizidwa ndi PD-1 inhibitors.Zotsatira zake: Zowonjezereka zowonjezereka zokhudzana ndi chitetezo cha mthupi poyerekeza ndi PD-1 inhibitors okha.Kuphatikizika kwa ChemotherapyNgakhale kuti mankhwala ochiritsira omwe akugwiritsidwa ntchito ndi ma immunotherapies asintha chithandizo cha NSCLC, chemotherapy imakhalabe njira yofunikira, makamaka kuphatikiza ndi mankhwala ena. Chithandizo chatsopano cha khansa ya m'mapapo yosakhala yaying'ono Nthawi zambiri amaphatikiza kuphatikiza mankhwala amphamvu a chemotherapy ndi immunotherapy kapena njira zochiritsira zomwe akuzifuna kuti ziwongolere bwino. mankhwala atsopano osakhala ang'onoang'ono a khansa ya m'mapapo. Njirayi imathandizira mphamvu ya chemotherapy kuwononga maselo a khansa ndikutulutsa ma antigen, kuwapangitsa kukhala otengeka kwambiri ndi chitetezo chamthupi. Kuphatikiza kwa immunotherapy kumatha kukulitsa kuyankha kwa chitetezo chamthupi, kumabweretsa zotsatira zabwino.Ubwino: Kupititsa patsogolo kupulumuka ndi kuyankha kwachangu poyerekeza ndi chemotherapy yokha.Zotsatira zake: Kuwonjezeka kwa chiopsezo cha chemotherapy komanso zotsatira zokhudzana ndi chitetezo cha mthupi.Kuphatikizika Kwachindunji ndi Chemotherapy Nthawi zina, kuphatikiza chithandizo chamankhwala ndi chemotherapy kungakhale kopindulitsa, makamaka kwa odwala omwe ayamba kukana chithandizo chamankhwala okha. Njirayi ingathandize kuthana ndi njira zotsutsa ndikuwongolera zotsatira za chithandizo.Ubwino: Itha kubwezeretsanso chidwi chamankhwala omwe akuwunikiridwa ndikuwongolera kupulumuka.Zotsatira zake: Kuwonjezeka kwa chiopsezo cha zotsatira zoyipa kuchokera kumankhwala onse awiri.Mayesero a Zachipatala: Tsogolo la Chithandizo cha NSCLC Mayesero achipatala ndi maphunziro ofufuza omwe amawunika. mankhwala atsopano osakhala ang'onoang'ono a khansa ya m'mapapo ndi njira. Kutenga nawo mbali pazachipatala kungapereke mwayi wopeza chithandizo chamakono chomwe sichinapezeke kwambiri. Shandong Baofa Cancer Research Institute yadzipereka kupititsa patsogolo kafukufuku wa khansa ndipo imapereka chithandizo ndikuchita nawo mayesero azachipatala omwe amapereka mwayi wopeza chithandizo chamakono chomwe sichinapezekebe. Dziwani zambiri za mayeso azachipatala ku Shandong Baofa Cancer Research Institute.Emerging Therapies in Clinical TrialsZochuluka zolonjeza mankhwala atsopano osakhala ang'onoang'ono a khansa ya m'mapapo akuwunikidwa pano m'mayesero azachipatala, kuphatikiza:Antibody-drug conjugates (ADCs): Mankhwalawa amapereka chemotherapy mwachindunji ku maselo a khansa, kuchepetsa kuwonongeka kwa maselo athanzi.Ma antibodies a Bispecific: Ma antibodies awa amamangiriza ku maselo onse a khansa ndi maselo a chitetezo chamthupi, kuwabweretsa pamodzi kuti apititse patsogolo chitetezo chamthupi.Chithandizo cha ma cell (monga ma cell a CAR-T): Mankhwalawa amaphatikizapo kusintha maselo a chitetezo cha mthupi kuti awononge ndi kuwononga maselo a khansa.Kukhala ndi NSCLC: Zothandizira ndi ThandizoKukhala ndi NSCLC kungakhale kovuta, koma zida zambiri ndi magulu othandizira alipo kuti athandize odwala ndi mabanja awo kuthana ndi matendawa. Ganizirani zofufuza zothandizira kuchokera kumabungwe ngati American Lung Association kapena LUNGevity Foundation.Chodzikanira: Nkhaniyi ndi yongofuna kudziwa zambiri ndipo siyenera kutengedwa ngati upangiri wachipatala. Chonde funsani ndi wothandizira zaumoyo wanu kuti akupatseni malangizo omwe akukuthandizani.